SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001104659-22-130714
Filing Date
2022-12-29
Accepted
2022-12-29 09:16:42
Documents
14
Period of Report
2022-12-29
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2233528d1_8k.htm   iXBRL 8-K 24224
2 EXHIBIT 99.1 tm2233528d1_ex99-1.htm EX-99.1 51557
6 GRAPHIC tm2233528d1_ex99-1img01.jpg GRAPHIC 9494
  Complete submission text file 0001104659-22-130714.txt   276614

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA otlk-20221229.xsd EX-101.SCH 3322
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE otlk-20221229_lab.xml EX-101.LAB 34986
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE otlk-20221229_pre.xml EX-101.PRE 22617
8 EXTRACTED XBRL INSTANCE DOCUMENT tm2233528d1_8k_htm.xml XML 3695
Mailing Address 485 ROUTE 1 SOUTH BUILDING F, SUITE 320 ISELIN NJ 08830
Business Address 485 ROUTE 1 SOUTH BUILDING F, SUITE 320 ISELIN NJ 08830 6096193990
Outlook Therapeutics, Inc. (Filer) CIK: 0001649989 (see all company filings)

IRS No.: 383982704 | State of Incorp.: DE | Fiscal Year End: 0930
Type: 8-K | Act: 34 | File No.: 001-37759 | Film No.: 221496475
SIC: 2836 Biological Products, (No Diagnostic Substances)